Juxtaposition of Coeliac Disease and Type 1 Diabetes; the Role of Shared Non-human Leukocyte Antigen Loci

Iraj Shahramian1, Hossein Shahdadi2, Ali Bazi1,4*, Nosratollah Masinaeinezhad1, Mojtaba Delaramnasab3,4

1Pediatric Ward, Amir-Al-Momenin Hospital, Zabol University of Medical Sciences, Zabol, Iran
2Faculty of Nursing, Zabol University of Medical Sciences, Zabol, Iran
3Faculty of Allied Medical Sciences, Zabol University of Medical Sciences, Zabol, Iran
4Clinical Research Development Unit, Amir-Al-Momenin Hospital, Zabol University of Medical Sciences, Zabol, Iran

*Correspondence to Ali Bazi, Clinical Research Development Unit, Amir-Al-Momenin Hospital, Zabol University of Medical Sciences, Zabol, Iran
Tel/Fax: +98512239031; Email: m.bazilai@gmail.com

Abstract
Although extensive studies have been performed to explore the role of various alleles within the human leukocyte antigen (HLA) in susceptibility to coeliac disease (CD) and type 1 diabetes (T1D), less attention has been dedicated to the role of shared non-HLA loci. In the present report, we have provided a review on the role of genetic variants in seven shared non-HLA loci in determining the risk of either CD or T1D. The literature search was done on the Web of Knowledge, PubMed, and Scopus databases using keywords of polymorphism, coeliac disease, and type 1 diabetes. The literature published within 2000-2017 were recruited. Seven discussed shared loci between CD and T1D were those resided within cytotoxic T-lymphocyte associated protein 4 (CTLA4), regulator of G protein signaling (RGS1), SH2B adaptor protein (SH2B3), T cell activation Rho GTPase activating protein (TAGAP), interleukin 18 receptor accessory protein (IL18RAP), protein tyrosine phosphatase, non-receptor type (PTPN2), and C-C motif chemokine receptor (CCR5). The interaction between polymorphisms of these genes seems to exert a substantial impact on determining the risk of CD and T1D in context of each other. Polymorphisms residing in these loci can exert synergistic or opposing effects toward either protection or predisposition to CD and T1D. The majority of these polymorphisms affect the function of cytokine signaling or T cell activating pathways. The net outcome seems to be delineated by a complex interaction between these adaptor arms, as well as the modulatory effects of other components of immune system, in particular, HLA alleles.

Keywords: Coeliac disease, Type 1 diabetes, Single nucleotide polymorphism, Human leukocyte antigen

Introduction
Coeliac disease (CD), an autoimmune disorder inflicting gastrointestinal system, is a common enteropathy characterized with intestinal inflammation.1 Gluten deems to be the major environmental trigger for progression of an aberrant immune reaction against the intestinal wall in the CD. Being an autoimmune disease in nature, CD has been reported in association with a variety of other autoimmune conditions including type 1 diabetes (T1D).2,3 It has been estimated that 8% of patients with T1D can be diagnosed with CD in the course of their diseases indicating a significant higher co-association rate than general population.

Progression of CD in the context of T1D can exaggerate and complicate the clinical course T1D. In fact, T1D patients with concurrent CD have presented higher propensity for cardiovascular complications, metabolic disorders, renal insufficiency, and retinopathy.4,7 Based on these, it is of critical importance to divulge risk factors of CD in the context of T1D.

Genetic susceptibility is a main factor in predicting the risk of various human diseases, including both CD and T1D. Among these genetic loci are human leukocyte antigen (HLA) genes. In fact, HLA-DQ2 and HLA-DQ8 are 2 well-
known shared risk factors for both CD and T1D. Nearly all patients with CD reveal either HLA-DQ2 (95%) or HLA-DQ8 (5%) upon HLA typing. Interestingly, HLA-DQ alleles are also mapped in nearly one-third of T1D cases. Overall, inheritance of certain HLA alleles has been well established to be associated with the risk of CD-T1D coexistence. Although the role of HLA loci has been extensively evaluated in risk association studies, there are few remarks on the impact of non-HLA genetic loci in determining the risk of CD and T1D co-development. In the present review, we have focused on a number of proposed shared non-HLA genetic loci and their possible interactions in determining the risk of either CD or T1D.

Search Strategy
A comprehensive search was done on the Web of Knowledge, PubMed, and Scopus databases using keywords of polymorphism, coeliac disease, and type 1 diabetes. The star: “*” truncation was applied as “C*eliac” to recruit differentially spelled forms in Web of Knowledge and Scopus. Time spans included literature published within 2000-2017, and those assessed one of the shared genetic loci reported by Smyth et al.10

Shared Non-HLA Loci Between CD and T1D
Until recently, 42 non-HLA genes loci have been identified to modulate the risk and progression of the CD. Among these, 7 shared loci have been proposed between CD and T1D so far (Table 1).10 In the following sections, we have discussed the potential role of these shared loci in determining the risk of CD and T1D development.

Cytotoxic T-Lymphocyte Associated Protein 4
Up to date, there have been about 100 polymorphic loci identified at the locus of cytotoxic T-lymphocyte associated protein 4 (CTLA4) gene at chromosome 2q33. Some polymorphisms residing in CTLA4 locus (i.e. SNPs of CT60 G>A (rs3087243) and AG49 (rs231775)) have been correlated with lower levels of CTLA-4. The rs5742909 (-318 C/T) is another polymorphism located in the promoter region of CTLA-4 gene. Nevertheless, no significant impact was identified for this variant with neither CD nor T1D.27 The role of CT60 G>A (rs3087243) polymorphism has been noted in some autoimmune disorders.46-49 Reports of the impact of this polymorphism on protective or predisposing effects toward either CD and T1D have been conflicting. Smyth et al have considered a protective role for this polymorphism against both CD and T1D.10 However, others have asserted a predisposing impact for this polymorphism for either CD or T1D.13-15 However, the susceptibility toward T1D has been noted for the wild-type allele at this locus.13-15 Based on this, one can comprehend a parallel protective role for the minor allele (A) of this locus as noted in the study of Smyth et al.10 Based on a proposed recessive mode for this polymorphism, general idea is that only homozygous wild-type combination of rs3087243 is associated with elevated risk for autoimmunity.40 In fact, G allele of this polymorphism has been associated with depressed expression of CTLA-4.41

Inheritance of rs231775 (+49 A/G) polymorphism was shown to be linked to dampen levels of CTLA-4 in both plasma and cell surface of T lymphocytes.45 These reduced levels, which subsequently lead to lower immunomodulatory effects of CTLA-4, have been accompanied with a higher rate of autoimmune conditions such as T1D, Graves disease, and graft rejection in transplanted individuals.46,47 Multiple studies have noted predisposing role for minor G allele of this polymorphism for CD18 and T1D.13,15,19-24 Two studies; Mora et al, Nalau et al16,17 have observed the higher risk of CD in individuals bearing the wild-type A allele of this polymorphism. On the other hand, some have not reported any significant association between this polymorphism with the occurrence of CD13,15 and T1D.26,27 Synergistic effects of CT60 G>A and +49 A/G polymorphisms of CTLA-4 gene has been noted as a dominant risk factor for the development of polyglandular autoimmunity (OR=4.89, 95% CI: 1.86-13.59).40

Inheritance of two G alleles at the +49 locus within CTLA-4 gene result in a low functional index of CTLA-4. Nevertheless, individuals with homozygote signature for A allele may also develop autoimmune conditions indicating a multidisciplinary interaction for deterring risk of autoimmunity.48 Actually, immune reactions are dependent on a complex interaction of non-HLA loci mediators with those of HLA II alleles. This is substantially important as HLA II molecules impart a significant role in antigen presentation to reactive T lymphocytes.

The function of T lymphocytes is negatively regulated by CTLA-4. Therefore, low activity of this molecule results in deregulated activation of T lymphocytes predisposing to autoimmune disorders. In fact, the use of immune checkpoint inhibitors (ICIs); ipilimumab (anti-CTLA-4), which has been proposed as an immunotherapy approach in malignancies, has been debated due to the possibility of an increased rate of autoimmune disorders.40,41 This molecule functionally belongs to immunoglobulin proteins and is highly detectable on the surface of T lymphocytes. In particular, CTLA-4 is identifiable in considerable copy numbers on the surface of regulatory T lymphocytes (CD4+CD25+FoxP3+) and also cytotoxic activated T cells.30,31 Recently, it has been proposed that regulatory T cells prevent autoimmune reactions through inhibition of dendritic cells (DCs) in a CTLA-4 dependent way.52 CTLA-4 has been noted to counterbalance the signaling pathways originated form activator complexes on the surface of activated T lymphocytes namely CD28-B7. In fact, both CTLA-4 and CD28 are ligands for B7 family receptors on T lymphocyte membrane. However, CTLA-4 and CD28
Table 1. Shared Non-HLA Loci Associated With Both Celiac Disease and Type 1 Diabetes in Children

<table>
<thead>
<tr>
<th>Non-HLA Loci* (Chromosome Location)</th>
<th>SNP</th>
<th>Effector Allele</th>
<th>Effects</th>
<th>Celiac Disease</th>
<th>Type 1 Diabetes</th>
</tr>
</thead>
<tbody>
<tr>
<td>CTLA-4, 2q33.2</td>
<td>rs3087243 (CT60 G&gt;A)</td>
<td>A</td>
<td>Pro</td>
<td>Smyth et al10</td>
<td>Smyth et al10</td>
</tr>
<tr>
<td></td>
<td>rs231775 (-49 A/G)</td>
<td>G</td>
<td>Sus</td>
<td>Mora et al, Naluai et al13,17,18, El-Akawi et al10</td>
<td>Dallos et al, Jin et al, Wang et al15,16,17</td>
</tr>
<tr>
<td></td>
<td>rs5742909 (-318 C/T)</td>
<td>T</td>
<td>Ns</td>
<td>Song et al12</td>
<td>Celmeli et al, Tavares et al25,26</td>
</tr>
<tr>
<td>TAGAP, 6q25.3</td>
<td>rs1738074</td>
<td>A</td>
<td>Pro</td>
<td>-</td>
<td>Smyth et al10</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sus</td>
<td>Romanos et al18</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ns</td>
<td>Amundsen et al, Plaza-Izurieta et al29,10</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>IL-18RAP, 2q12.1</td>
<td>rs2816316</td>
<td>G</td>
<td>Pro</td>
<td>-</td>
<td>Smyth et al10</td>
</tr>
<tr>
<td></td>
<td>rs917997</td>
<td>A</td>
<td>Sus</td>
<td>Amundsen et al, Plaza-Izurieta et al29,10</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>rs13015714</td>
<td>G</td>
<td>Ns</td>
<td>Amundsen et al10</td>
<td>-</td>
</tr>
<tr>
<td>PTPN2, 18p11.21</td>
<td>rs476582</td>
<td>G</td>
<td>Pro</td>
<td>Smyth et al10</td>
<td>Smyth et al10</td>
</tr>
<tr>
<td></td>
<td>rs2542151</td>
<td>G</td>
<td>Pro</td>
<td>-</td>
<td>Peng et al31</td>
</tr>
<tr>
<td></td>
<td>rs45450798</td>
<td>G</td>
<td>Sus</td>
<td>Smyth et al10</td>
<td>Smyth et al10</td>
</tr>
<tr>
<td></td>
<td>rs1893217</td>
<td>C</td>
<td>Ns</td>
<td>-</td>
<td>Reddy et al, Rheinheimer et al24,42</td>
</tr>
<tr>
<td>RGS1, 1q31.2</td>
<td>rs2816316</td>
<td>C</td>
<td>Pro</td>
<td>Amundsen et al, Romanos et al, Guo et al, Plaza-Izurieta et al28,30,33</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sus</td>
<td>-</td>
<td>Parkkola et al14</td>
<td>-</td>
</tr>
<tr>
<td>SH2B3, 12q24.12</td>
<td>rs3184504</td>
<td>T</td>
<td>Sus</td>
<td>Romanos et al, Guo et al24,45</td>
<td>Smyth et al, Reddy et al, Steck et al, Nikitin et al24,46,47</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ns</td>
<td>Plaza-Izurieta et al29</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>CCR5, 3p21.31</td>
<td>rs333 (Delta 32 polymorphism- 32-bp deletion)</td>
<td>-</td>
<td>Pro</td>
<td>Smyth et al10</td>
<td>Smyth et al, Slominski et al, Buhler et al23,38,39</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sus</td>
<td>Slominski et al38</td>
<td>-</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviation: SNP; single nucleotide polymorphism, Pro; protection, Sus; susceptibility, Ns; no significant effect; CTLA-4, cytotoxic T-lymphocyte associated protein 4; TAGAp, T cell activation Rho GTPase activating protein; SH2B3, SH2B adaptor protein; IL-18RAP, interleukin 18 receptor accessory protein; RGS1, regulator of G protein signaling; CCK5, C-C motif chemokine receptor; PTPN2, protein tyrosine phosphatase non-receptor type.

*a Selection of these shared loci are based on the report of Smyth et al, 2008.10

*b Susceptibility associated with G allele.

c Susceptibility associated with A allele.

**Competitively bind and negatively and positively regulate T cell function respectively.**44,53 Signaling pathways activated by the CTLA-4 was shown to induce tolerance against the development of autoimmune conditions.44 In vitro blockage of CTLA-4/B7 complexes suppressed the proliferative activity of T lymphocytes in response to mitotic stimulators. The mechanisms for inhibitory effects of CTLA-4 are not fully understood, however, hindering from formation of CD28/B7 stimulatory complexes has been observed as a potential factor.

**Regulator of G Protein Signaling**

This molecule belongs to the family of regulator of G-protein signaling (RGS). The risk of some autoimmune disorders, including T1D, has been higher in carriers of polymorphism within RGS1 gene. The function of RGS1 is critical for recruitment of lymphocytic population into the lymphoid organ. This is achieved by modulation of chemokine receptor functions; CCR7 and CXCR4, by RGS1.56-57 Through its potent GTPase activity, RGS1 suppresses signaling pathways originated form
chemokine receptors. In fact, RGS1 degrades G-proteins which are mandatory downstream messengers for cellular signaling activities. There are multiple reports indicating a significant protection against CD in individuals bearing the C allele of rs2816316 polymorphism mapped on RGS1 gene. In contrast, inheritance of this variant has been noted in association with a higher chance of being affected with T1D.

**SH2B Adaptor Protein**

As for the genetic loci in the previous section, SH2B adaptor protein (SH2B3) also modulates signaling pathways derived from inflammatory cytokines and suppresses the proliferative activity of B and T lymphocytes. In particular, SH2B3 is a master regulator of the intracellular interaction of signaling adaptors participating in inflammatory reactions. Due to the presence of conserved SH2 domain, these variant molecules of SH2B3 can inhibit formation and interaction of the NOD2 intracellular receptor and modulate ERK1/2 and p38MAPK pathways. Importance of the rs3184504 polymorphism within SH2B3 is highlighted as carriers of the minor allele (T) at this locus are more prone to both CD and T1D.

**T Cell Activation Rho GTPase Activating Protein**

A single polymorphism (rs1738074), a variation mapped within the 5’-UTR region of the T cell activation Rho GTPase activating protein (TAGAP) gene, was noted to confer a protection against T1D. Complementary to this, Romanos et al described an elevated risk of CD in individuals with minor (A) allele of this polymorphism. In contrast, Amundsen et al and Plaza-Izurieta et al stated no impacts regarding inheritance of this genetic variant with susceptibility to CD.

Polymorphisms within TAGAP, located at 6q25, have been accompanied by various autoimmune diseases including CD. As mentioned for RGS1, TAGAP also acts as an activator for GTase functionality within cells. Nevertheless, TAGAP activates a specific GTase unique for RhoA molecule which is merely expressed within activated T lymphocytes. Especially, TAGAP activation is critical in cytoskeleton rearrangements and migration of T lymphocytes. Furthermore, TAGAP also binds RhoH; a molecule which interacts with Lck and ZAP70 molecules downstream to T cell receptor (TCR) cytoplasmic domain. Through this, TAGAP precludes ZAP70 from interacting with RhoH and suppresses TCR signaling. Recently, TAGAP has been proposed as a potential target for induction of Th17 lymphocytes which are modulatory populations against autoimmune disorders.

**Interleukin 18 Receptor Accessory Protein**

Interleukin 18 receptor accessory protein (IL18RAP) is one component of heterodimeric IL-18R. The other subunit of this receptor is known as IL18R1. This complex is highly detectable on the surface of immune cells including T lymphocytes. During T cell activation and particularly in response to IL-12, IL-18RAP is activated and contributes to intracellular signaling pathways in lymphocytes.

Polymorphisms within the IL18RAP seem to exert antithetical roles in the development of CD and T1D. While rs2816316 (G minor allele) polymorphism was identified to protects against T1D, an elevated risk of CD has been described for carriers of rs917997 polymorphism. On the other hand, rs917997 polymorphism has been described as a protective factor against T1D while a risk factor for CD in another report. The rs917997, a polymorphism located in the 3’ UTR, has been accompanied by depressed levels of IL18RAP in the serum of individuals with CD. Another polymorphism of this gene, rs13015714 was not found to exert a significant influence on the occurrence of CD.

**Protein Tyrosine Phosphatase Non-receptor Type**

Smyth et al have drawn conflicting conclusions regarding the role of 2 polymorphisms of this gene; rs478582 and rs45450798, regarding their protective and predisposing roles for CD respectively. In the same report, these researchers also found parallel effects of these polymorphisms regarding T1D (i.e. a protective role for rs478582 and a predisposing role for rs45450798).

Furthermore, Peng et al have noted lower odds for development of T1D in subjects with minor (G) allele of rs2542151 polymorphism of protein tyrosine phosphatase non-receptor type (PTPN2) gene. In 2 additional reports, no significant association was reported between rs1893217 polymorphism of PTPN2 gene with T1D.

The majority of polymorphic sites within PTPN2 reside with intronic regions. These variants are supposed to give rise to alternative splicing sites resulting in altered stability of mRNA or non-sense frameshifts as well as epigenetic consequences, which all lead to altered bioavailability of the protein.

Both T1D and gastrointestinal disorders such as inflammatory bowel disease, Crohn disease as well as autoimmune disorders such as rheumatoid arthritis have been noted in association with polymorphisms within non-coding regions of PTPN2. As for some of the previously mentioned loci, PTPN2 is also closely related to regulation of cytokine signaling.

PTPN2 belongs to a family of dephosphorylating enzymes breaking phosphates from tyrosine residues within the cytoplasmic domain of cytokine receptors. Regarding functional activity, PTPN2 is particularly important in the regulation of T lymphocytes toward both self and foreign antigens. This observation has been accompanied by promoted...
activities of T and B lymphocytes as well as higher levels of proinflammatory cytokines.\textsuperscript{76}

C-C Motif Chemokine Receptor

C-C motif chemokine receptor (CCR5) is involved in the recruitment of immune cells, including innate immunity cells such as T lymphocytes, to inflamed tissues. CCR5 is particularly bound to chemokine ligand 5, an attractant expressed by T lymphocytes, macrophage inflammatory protein-1, and monocyte chemoattractant protein-2.\textsuperscript{77} A common genetic variant of CCR5, a 32 base pair deletion (rs333, 32-bp deletion), has been widely studied as a functional polymorphism within this gene. Homozygosity for this variant has been associated with dim expression of CCR5 on the cell membrane.\textsuperscript{78}

Smyth et al\textsuperscript{38} and Słomiński et al\textsuperscript{39,79,80} declared conflicting results regarding the impact of this polymorphic variant of CCR5 gene in the progression of CD (protective vs. predisposing respectively). In studies on T1D patients, however, multiple reports have stipulated a protective role for this polymorphism.\textsuperscript{10,38,79,80}

Conclusion

Immune disorders are associated with aberrant regulation of immune functions. T1D and CD are two common forms of autoimmune diseases concomitantly observed in the considerable ratio of individuals. Although HLA loci play an important role in the determination of susceptibility to either CD and T1D, the role of shared non-HLA loci is less characterized. It seems that interaction of polymorphic variants of genes involved in regulation of immune cell activities, in particular T lymphocytes, with each other and with HLA loci to be critical in determining the risk of T1D and CD in the context of each other. Large population-based studies are warranted to explore the role of these loci in future studies.

Ethical Approval

Not applicable.

Competing interest

None.

References


Shahramian et al

66. Doody KM, Bourdeau A, Tremlay ML. T-cell protein tyrosine phosphatase is a key regulator in immune cell signaling: lessons from the knockout mouse model